Female orgasmic disorder? CBC airs indepth disease-mongering discussion

The Canadian Broadcasting Corporation’s (CBC) program, The Current, reported: “Drug to treat Female Orgasmic Disorder under speculation.”

The brief program description:

“Trials of a new drug to help treat a condition known as female orgasmic disorder are underway in Canada. But critics say there’s no such thing, and this is really about drug manufacturing and marketing.”

The healthy skeptic on the program (about 12 minutes deep in the audio below) was Dr. Barbara Mintzes, Assistant Professor in the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia. The main focus of her research is on the effects of drug promotion, including direct-to-consumer advertising, on prescribing and medicine use. She also works with UBC’s Therapeutics Initiative to carry out systematic reviews on the beneficial and harmful effects of new drugs. She’s also co-author of the book, “Sex, Lies and Pharmaceuticals: How Drug Companies Plan to Profit from Female Sexual Dysfunction.”

PLAY THE PROGRAM HERE

The program is a classic discussion of concerns about disease-mongering. Kudos to CBC and The Current for educating listeners. It’s a 24-minute program well worth your time.

You might also like

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.

Comments are closed.